Roth Capital Markets analyst Boobalan Pachaiyappan said in a Nov. 25 report that Capricor Therapeutics’ (Capricor Therapeutics Stock Quote, Chart, News, Analysts, Financials NASDAQ:CAPR) sharp decline on Nov. 24 — a 19% drop versus a 3% gain for the S&P’s biotech ETF XBI — was driven by a short seller’s note that questioned the profile […]
In a Nov. 24 update, Research Capital analyst André Uddin maintained his “Speculative Buy” rating and $7.70 target price on NervGen Pharma (NervGen Pharma Stock Quote, Chart, News, Analysts, Financials TSXV:NGEN), which is developing NVG-291 for the treatment of spinal cord injury. Vancouver-based NervGen reported no third-quarter revenue, matching expectations and unchanged from a year […]
Share
Tweet
Share
